Brind.

BridgeBio is seeking Accelerated Approval from the FDA for a treatment that utilizes increased TTR stabilization, showing positive results for CVH events.

2 reports, 2 independent Updated Jul 2

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

BridgeBio is seeking Accelerated Approval from the FDA for a treatment that utilizes increased TTR stabilization, showing positive results for CVH events.

Who's involved

What this event is mainly about

BridgeBio TTR FDA

Keep exploring

The entities involved

BridgeBio
company in Palo Alto, United States
- BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
TTR
Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Jul 2manilatimes.net
Aug 6GlobeNewswireBridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an